Research demonstrates elevated levels of VEGF-C, VEGF-D, and CXCL-12 in diabetic kidney disease, indicating their potential as biomarkers for severity assessment.
Key Points
Plasma levels of VEGF-C, VEGF-D, and CXCL-12 significantly increase in all diabetic kidney disease groups.
Correlation analysis shows higher plasma VEGF levels relate to increased creatinine and urinary microalbumin levels.
The area under the curve for AUC-ROCs indicates VEGF-D is particularly effective for distinguishing stages of diabetic nephropathy.
These findings support using VEGF-C, VEGF-D, and CXCL-12 as biomarkers for early diagnosis and monitoring of diabetic kidney disease.